Antibody molecules which bind IL-17A and IL-17F
View Patent ↗The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
1. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, and wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, or an antigen binding fragment thereof.
2. The antibody according to claim 1 , where the antibody fragment is a Fab, Fab′, F(ab′)2, or scFv.
3. The antibody according to claim 1 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
4. The antibody according to claim 1 , wherein the antibody is a multi-specific antibody or antigen binding fragment thereof.
5. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the heavy chain comprises the sequence given in SEQ ID NO: 9.
6. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the light chain comprises the sequence given in SEQ ID NO: 7.
7. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO: 9 and a light chain comprising the sequence given in SEQ ID NO: 7.
8. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO: 15 and a light chain comprising the sequence given in SEQ ID NO: 11.
9. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the antibody binds to the same epitope on human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer as a neutralising antibody which binds human IL-17A and human IL-17F and has a heavy chain comprising the sequence given in SEQ ID NO: 9 and a light chain comprising the sequence given in SEQ ID NO: 7.
10. The antibody according to claim 9 , wherein the antibody or fragment thereof is a CDR-grafted antibody.
11. A pharmaceutical composition comprising an antibody according to any one of claims 1 , 7 , 8 or 9 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
12. A pharmaceutical composition according to claim 11 , additionally comprising other active ingredients.